Conclusions: Total hospitalisation costs of TAVI amount to about €40,000. Main cost driver is length of stay and valve cost. Costs decrease marginally over time. Most patient characteristics are not significantly related to total hospitalisation costs.
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30-day Outcome of the 18 F-Direct Flow Medical Valve in Patients with Severe Aortic Stenosis -Results from the DISCOVER Trial
ICPS, Massy, France
Background: For currently available percutaneous aortic valve prosthesis, device design limitations and potential misplacement can lead to significant aortic regurgitation, which can result in severe complications and have an impact on long-term survival. The Direct Flow Medical (DFM) valve is repositionable and retrievable and has non metallic inflatable cuff with a conformable design that results in better valve sealing. Compared to the first generation, the new 18F prosthesis, has a smaller profile, increased radial force and better handling. We report the first series of high risk patients who received the 18F DFM transfemoral prosthesis for severe aortic stenosis. Aim of the study was to test the safety and performance of the 18F Direct Flow Medical valve in high risk patients with severe aortic stenosis. Methods: In this prospective, multicenter, non-randomized clinical trial 100 symptomatic patients with severe aortic stenosis and a logistic Euro-SCORE Ն 20% will be enrolled.
The primary endpoint is freedom from all-cause mortality @ 30 days, secondary endpoints were device success and safety according to the VARC criteria. Data are monitored and events adjudicated by independent committees (DMC, CEC). All echocardiograms and angiograms were assessed by an independent Core Laboratory.
Results:
The study started in January 2012 in 5 centers in Europe. Five additional centers will follow. As of May 2012, 25 patients have been enrolled (mean age 84.9 y, 76-95 yrs, mean logistic Euro-Score 27.9%, mean STS 11%). The primary endpoint of freedom from death at 30 days was achieved in all 25 patients. The valve was retrieved and reimplanted in 4 patients. At present, 10 pts had core lab evaluation, revealing a mean transvalvular gradient at 30 days of 11 mmHg. There was no aortic regurgitation in 8 pts and 2 had trace aortic regurgitation.
Conclusions:
The 18F DFM valve can be safely implanted, repositioned and, if necessary retrieved in high risk patients with severe aortic stenosis. Preliminary results suggest excellent hemodynamic performance with abolishing significant aortic regurgitation. The results of the completed study will be available at TCT 2012. Background: Transcatheter aortic valve replacement (TAVR) is the first major addition to the treatment of valvular heart disease in more than a decade, and the number of patients eligible for valve replacement is likely to increase significantly. As a consequence, little is known about expectations within the cardiology community regarding the utilization of this new therapy in clinical practice. Methods: Four days after approval of the first TAVR device in November 2011 by the U.S. Food and Drug Administration (FDA), we emailed an online questionnaire to 201 cardiologists involved in TAVR research and 461 recent members of the Society of Cardiac Angiography and Interventions to evaluate anticipated TAVR referral patterns. Follow-up reminders were sent during the next 4 weeks. Characteristics between researchers and clinicians were compared using chi-square and t-tests. Results: Of 205 responses received (31%), the majority of respondents were male (90%), interventional cardiologists (86%), and working in academic practices (72%). Most respondents (90%) planned to refer patients for TAVR immediately after the devices are clinically available, and 70% stated that no more data were needed to confirm TAVR is safe for clinical use. Although 75% of respondents anticipated referring less than one-fourth of their patients with severe aortic stenosis for TAVR, 68% believed that TAVR is equally efficacious as open-heart surgery, and 11% believed that moderatesurgical risk patients should also be referred for TAVR. When comparing groups of respondents, those involved in TAVR research studies were more conservative with regard to anticipated referral patterns, as 81% would refer as soon as TAVR is clinically available versus 98% of clinical cardiologists (pϽ0.01). Conclusions: These data provide insight into the expected utilization of TAVR after FDA approval in November 2011. Despite remarkable enthusiasm and media attention for TAVR over the past few years, our findings suggest cautious optimism among the U.S.
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Long-term performance of a transfemorally implantable nonmetallic, retrievable and repositionable aortic valve in patients with severe aortic stenosis 4 Year Follow-Up of the 22 F-Direct Flow Medical Valve
interventional cardiology community regarding the uptake of this new approach to managing severe aortic stenosis.
TCT-817
Transcatheter , pϭ0 .75). The most common complications involved peripheral arterial accesses (4.8%). BAV was performed in patients with CAD (Nϭ17) concomitant with PCI and in patients with carcinoma (Nϭ7) that underwent major non-cardiac surgery. During 6 months follow up a restenosis of dilated valve occurred (restenosis rate 59%). Recurrence of symptoms was resolved with another BAV (2 BAV Nϭ22, 3 BAV Nϭ3) or TAVI (Nϭ22). During the follow up a trend towards better outcome was noted in the TAVI patients. There was no impact of EBRT on restenosis and on survival rate (Fig.1) . 
